The project VacPath – Novel vaccine vectors to resist pathogen challenge – is a PhD training program supported by the European Union under the Marie Sklodowska-Curie actions (MSCA) – Innovative Training Networks (ITN). VacPath aims to develop novel vector-based vaccines eliciting mucosal immunity against the intracellular bacterium Chlamydia trachomatis. This bacterium is an important cause of sexually-transmitted disease, and poses a major public health problem world-wide Knowledge obtained in this project may translate into the development of vaccines against viral and intracellular bacterial pathogens, as needed, addressing a current societal and economical need for vaccines to tackle emerging and re-emerging pathogens.
The network joins five academic European research groups and two SMEs within The Netherlands, Germany, Switzerland, Denmark and Italy. This network cooperates in training 10 Early Stage Researcher (ESR) in the diverse aspects of novel vaccine development, to find creative solutions to future pathogen-imposed challenges.
|START DATE:||01 January 2019|
|PARTNERS:||7 from 5 countries|